Skip to main content
SpringerLink
Log in

Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia

  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Subanalyses of previous multicenter studies comparing lovastatin and gemfibrozil were carried out to evaluate the merits of these agents in patients with different serum lipid phenotypes (type 2a and 2b hyperlipoproteinemia). Regardless of phenotype, lovastatin was more effective in lowering LDL-cholesterol, while gemfibrozil had a greater triglyceride-lowering and HDL-cholesterol-increasing effect. Patients with type 2a phenotype benefited (in terms of serum lipid pattern) more from lovastatin. In type 2b hyperlipoproteinemia, more patients taking lovastatin than gemfibrozil reached both treatment goals defined by the European Atherosclerosis Society, (LDL-cholesterol4.0 mmol/Iandtriglycerides 2.3 mmol/1). In many patients these goals could not be met suggesting that multiple drug therapy may be indicated in part of the patients with type 2b hyperlipoproteinemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA (1987) Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237–1245

    PubMed  Google Scholar 

  2. Tikkanen MJ, Helve E, Jäättelä A, Kaarsalo E, Lehtonen A, Malbecq W, Oksa H, Pääkkönen P, Salmi J, Veharanta T, Viikari J, Aärynen M, and the Finnish Lovastatin Study Group (1988) Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The Finnish Multicenter Study. Am J Cardiol 62: 35J-43J

    PubMed  Google Scholar 

  3. Ojala J-P, Helve E, Tikkanen MJ, Jäättelä A, Kaarsalo E, Lehtonen A, Oksa H, Pääkkönen P, Salmi J, Snapinn S, Veharanta T, Viikari J, and the Finnish Lovastatin Study Group (1990) Switch from gemfibrozil to lovastatin therapy in patiens with primary hypercholesterolemia: a multicentre study. Drug Invest 2 [Suppl]: 40–47

    Google Scholar 

  4. Ojala J-P, Helve E, Tikkanen MJ (1990) Treatment of combined hyperlipidemia with lovastatin and gemfibrozil: a comparison study. Cardiology (in press)

  5. Helve E, Ojala J-P, Tikkanen MJ (1988) Simvastatin and gemfibrozil in the treatment of primary hypercholesterolemia. J Appl Cardiol 3: 381–388

    Google Scholar 

  6. Tikkanen MJ, Bocanegra TS, Walker F, Cook T, the Simvastatin Study Group (1989) Low-dose simvastatin vs. gemfibrozil in the treatment of elevated plasma cholesterol: a multicenter study. Am J Med 87: 47S-53S

    Google Scholar 

  7. Schulzeck P, Bojanovski M, Jochim A, Canzler H, Bojanovski D (1988) Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Lancet I: 611–613

    Google Scholar 

  8. European Atherosclerosis Society Study Group (1988) The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 9: 571–600

    Google Scholar 

  9. Ginsberg HN, Le N, Short MP, Ramakrishnan R, Desnick RJ (1987) Suppression of apolipoprotein B production during treatment of cholesterol storage disease with lovastatin: implications for regulation of apolipoprotein B synthesis. J Clin Invest 80: 1692–1697

    Google Scholar 

  10. Grundy SM, Vega GL (1987) Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 83: [Suppl 5B]:9–20

    Google Scholar 

  11. Nikkilä EA, Ylikahri R, Huttunen JK (1976) Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Proc R Soc Med 69: [Suppl 2]: 58–63

    Google Scholar 

  12. Tall AR (1986) Plasma lipid transfer proteins. J Lipid Res 27: 361–367

    PubMed  Google Scholar 

  13. Helve E, Tikkanen MJ (1988) Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. Atherosclerosis 72: 189–197

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Medicine, University of Helsinki, SF-00290, Helsinki, Finland

    M. J. Tikkanen

  2. Third Departments of Medicine, University of Helsinki, SF-00290, Helsinki, Finland

    J. -P. Ojala & E. Helve

Authors
  1. M. J. Tikkanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. -P. Ojala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Helve
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tikkanen, M.J., Ojala, J.P. & Helve, E. Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia. Eur J Clin Pharmacol 40, S23–S25 (1991). https://doi.org/10.1007/BF01409403

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01409403

Key words

Search

Navigation